AGP Executive Report
Last update: 10 hours agoBladder Cancer Treatment Update: The EU medicines watchdog CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative therapy for adults with resectable muscle-invasive bladder cancer, including patients regardless of cisplatin eligibility; a final European Commission decision is expected in Q4 2026, and it would also apply to Liechtenstein, Iceland and Norway. Short Bowel Syndrome Breakthrough: Zealand Pharma also received a positive CHMP opinion for Zeydovio (glepaglutide) for adults with short bowel syndrome, with results reported as two thirds achieving at least a 20% reduction in weekly parenteral support volume after 24 weeks. Local Health Politics: Liechtenstein’s abortion debate remains in focus after Parliament voted 13–12 for a 12-week time-limit regime, while the hereditary prince has signaled he intends to block it. Cross-Border Care & Health Policy: A separate report notes German-speaking health ministers meeting to strengthen cross-border cooperation in Luxembourg, relevant for regional care coordination.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/25341176-914428814-01ad1817b7d7bbd7494f74de9728eb3c6ed8f55d-653x367-100x56.png)
